Gastric Neoplasms is an active area of clinical research and therapeutic development covered by The Life Science Feed. Our editorial team tracks the latest clinical trials, treatment guidelines, regulatory updates, and scientific advances relevant to Gastric Neoplasms. Browse the latest articles below for in-depth analysis and evidence-based clinical insights.
FLOT Regimen Extends Survival in Resectable Gastric Adenocarcinoma
A phase 2/3 trial found that perioperative FLOT chemotherapy improved overall survival compared to ECF/ECX in patients with locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma. The docetaxel-based triplet regimen demonstrated ...
Zolbetuximab: A New First-Line Option for CLDN18.2-Positive Gastric Cancer?
Two Phase 3 trials, SPOTLIGHT and GLOW, demonstrate that zolbetuximab combined with chemotherapy significantly improves progression-free and overall survival in CLDN18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12